DAA-话题@MedSci - 梅斯（MedSci）

#DAA#

53篇内容 | 2509人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1361818, encodeId=02b01361818fd, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=Hepatology：效果评估：给予DAA治疗失败的HCV患者索非布韦-维帕他韦+利巴韦林24周, objectType=article, longId=100285, objectId=5411100285ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5411100285ad, replyNumber=0, likeNumber=78, createdTime=2017-06-02, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5411100285ad, moduleTitle=Hepatology：效果评估：给予DAA治疗失败的HCV患者索非布韦-维帕他韦+利巴韦林24周, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5411100285ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361817, encodeId=d76e136181e72, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=Hepatology：评估DAA方案对伴有丙型肝炎的肝肾移植受者的安全性与有效性：结果来自HCV-TARGET研究, objectType=article, longId=100239, objectId=c5c41002397e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5c41002397e, replyNumber=0, likeNumber=78, createdTime=2017-06-02, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5c41002397e, moduleTitle=Hepatology：评估DAA方案对伴有丙型肝炎的肝肾移植受者的安全性与有效性：结果来自HCV-TARGET研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c5c41002397e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361816, encodeId=642c136181624, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=[ADAA2017] 新证据：囤积障碍与强迫症大不同, objectType=article, longId=96244, objectId=b23a962442e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b23a962442e, replyNumber=0, likeNumber=102, createdTime=2017-04-20, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b23a962442e, moduleTitle=[ADAA2017] 新证据：囤积障碍与强迫症大不同, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b23a962442e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361815, encodeId=f0b71361815f4, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=Ann Intern Med：FDA批准的口服DAA药物有很高的HCV治愈率, objectType=article, longId=92953, objectId=c41492953b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c41492953b7, replyNumber=0, likeNumber=68, createdTime=2017-03-23, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c41492953b7, moduleTitle=Ann Intern Med：FDA批准的口服DAA药物有很高的HCV治愈率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c41492953b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361814, encodeId=714f136181464, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=治愈丙肝重磅新药将上市！本土DAA药物突围, objectType=article, longId=85913, objectId=382185913a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=382185913a3, replyNumber=0, likeNumber=80, createdTime=2016-12-30, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=382185913a3, moduleTitle=治愈丙肝重磅新药将上市！本土DAA药物突围, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=382185913a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361813, encodeId=6d96136181316, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=ILC 2016：MELD得分较高的患者应谨慎接受DAA治疗, objectType=article, longId=66619, objectId=ccaf66619dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccaf66619dc, replyNumber=0, likeNumber=68, createdTime=2016-04-19, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccaf66619dc, moduleTitle=ILC 2016：MELD得分较高的患者应谨慎接受DAA治疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ccaf66619dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361812, encodeId=d0d81361812b1, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=存在HCC史的患者近1/3在接受DAA治疗后复发, objectType=article, longId=66522, objectId=41656652216, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41656652216, replyNumber=0, likeNumber=67, createdTime=2016-04-16, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41656652216, moduleTitle=存在HCC史的患者近1/3在接受DAA治疗后复发, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=41656652216)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361811, encodeId=8b361361811ca, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=ADAA 2016：抑郁焦虑初级保健患者，将受益于计算机化CBT, objectType=article, longId=66357, objectId=94316635ec5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94316635ec5, replyNumber=0, likeNumber=77, createdTime=2016-04-12, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94316635ec5, moduleTitle=ADAA 2016：抑郁焦虑初级保健患者，将受益于计算机化CBT, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=94316635ec5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361810, encodeId=68171361810c8, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=ADAA 2016：研究表明焦虑和皮肤病存在相关性, objectType=article, longId=66245, objectId=029b66245a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=029b66245a9, replyNumber=0, likeNumber=91, createdTime=2016-04-10, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=029b66245a9, moduleTitle=ADAA 2016：研究表明焦虑和皮肤病存在相关性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=029b66245a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361809, encodeId=921d1361809ab, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=ADAA 2016：CRHR1受体拮抗剂对PTSD女性患者无效, objectType=article, longId=66101, objectId=3c526610125, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c526610125, replyNumber=0, likeNumber=64, createdTime=2016-04-07, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c526610125, moduleTitle=ADAA 2016：CRHR1受体拮抗剂对PTSD女性患者无效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3c526610125)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361808, encodeId=2f3a136180894, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=SUDAAN统计分析软件：在调查研究中复杂抽样中的应用, objectType=article, longId=34265, objectId=98233426580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98233426580, replyNumber=0, likeNumber=79, createdTime=2014-05-07, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98233426580, moduleTitle=SUDAAN统计分析软件：在调查研究中复杂抽样中的应用, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=98233426580)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361806, encodeId=ad0313618063f, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=DAA药物，逐一细说, objectType=article, longId=29417, objectId=8d672941e95, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d672941e95, replyNumber=0, likeNumber=85, createdTime=2014-01-16, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d672941e95, moduleTitle=DAA药物，逐一细说, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8d672941e95)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361807, encodeId=70e3136180e31, content=<a href='/topic/show?id=a88b564ea6' target=_blank style='color:#2F92EE;'>#DAA#</a>, objectTitle=DAA取代现有疗法尚需时日, objectType=article, longId=29418, objectId=621c29418c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=621c29418c3, replyNumber=0, likeNumber=60, createdTime=2014-01-16, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=621c29418c3, moduleTitle=DAA取代现有疗法尚需时日, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=621c29418c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

DAA

2020-05-29

qingting (审核中...)

前往app查看评论内容

#DAA#

Hepatology：效果评估：给予DAA治疗失败的HCV患者索非布韦-维帕他韦+利巴韦林24周

2017-06-02

qingting (审核中...)

前往app查看评论内容

#DAA#

Hepatology：评估DAA方案对伴有丙型肝炎的肝肾移植受者的安全性与有效性：结果来自HCV-TARGET研究

2017-06-02

qingting (审核中...)

前往app查看评论内容

#DAA#

[ADAA2017] 新证据：囤积障碍与强迫症大不同

2017-04-20

qingting (审核中...)

前往app查看评论内容

#DAA#

Ann Intern Med：FDA批准的口服DAA药物有很高的HCV治愈率

2017-03-23

qingting (审核中...)

前往app查看评论内容

#DAA#

治愈丙肝重磅新药将上市！本土DAA药物突围

2016-12-30

qingting (审核中...)

前往app查看评论内容

#DAA#

ILC 2016：MELD得分较高的患者应谨慎接受DAA治疗

2016-04-19

仁心济世 (审核中...)

前往app查看评论内容

#DAA#

存在HCC史的患者近1/3在接受DAA治疗后复发

2016-04-16

qingting (审核中...)

前往app查看评论内容

#DAA#

ADAA 2016：抑郁焦虑初级保健患者，将受益于计算机化CBT

2016-04-12

qingting (审核中...)

前往app查看评论内容

#DAA#

ADAA 2016：研究表明焦虑和皮肤病存在相关性

2016-04-10

qingting (审核中...)

前往app查看评论内容

#DAA#

ADAA 2016：CRHR1受体拮抗剂对PTSD女性患者无效

2016-04-07

qingting (审核中...)

前往app查看评论内容

#DAA#

SUDAAN统计分析软件：在调查研究中复杂抽样中的应用

2014-05-07

qingting (审核中...)

前往app查看评论内容

#DAA#

DAA药物，逐一细说

2014-01-16

qingting (审核中...)

前往app查看评论内容

#DAA#

DAA取代现有疗法尚需时日

2014-01-16

科室
- - 订阅+
  - 更多科室
工具
服务